copy of dr. camidge on the keynote-024 trial in nsclc
Published 5 years ago • 27 plays • Length 0:30Download video MP4
Download video MP3
Similar videos
-
1:27
dr. camidge on the keynote-024 trial in nsclc
-
1:18
dr. reck on the safety of pembrolizumab in keynote-024 in metastatic nsclc
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
1:37
dr. camidge on the alex trial in patients with alk nsclc
-
2:25
dr. gadgeel on updated keynote-189 data in nsclc
-
3:31
the keynote-024 precedent for advanced-nsclc treatment
-
0:36
dr. camidge on the fda approval of pembrolizumab for squamous nsclc
-
0:54
dr. bestvina on the keynote-407 trial in squamous nsclc
-
2:30
dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc
-
6:42
pseudoprogression with checkpoint inhibitors in non-small cell lung cancer
-
4:52
the keynote-407 trial in metastatic squamous nsclc
-
1:08
dr. horn on the fda approval of atezolizumab plus bevacizumab and chemotherapy in nsclc
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
1:50
dr. melissa johnson on atezolizumab in patients with nsclc
-
4:16
upfront pd-1 inhibitor monotherapy in advanced nsclc
-
1:51
dr. camidge on biomarker combinations in nsclc
-
1:00
dr. camidge on phase i study with azd9291 in nsclc
-
1:28
dr. camidge on ap26113 in patients with advanced malignancies